NEUREN PHARMACEUTICALS LIMITED

7.29%

$12.66

Market Cap $1.576B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

MEMPHASYS LIMITED

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.

Latest Threads

Tag

Subject

NEU

Share Price

252 253 254

14:44

15K

7.3M

14:44

Last post Little T

15K

7.3M

NEU

Ann: Neuren appoints Daryl DeKarske to executive team

14:34

4.9K

14:34

Last post DumbPostAvenger

4.9K

NEU

Ann: Update - Notification of buy-back - NEU

12:19

2.8K

12:19

Last post sarge17

2.8K

NEU

NEU Vs Reata

10:25

46K

10:25

Last post hottod

46K

NEU

Acadia

22 23 24

09:41

1.4K

713K

09:41

Last post kens

1.4K

713K

NEU

Ann: Update - Notification of buy-back - NEU

08:56

637

08:56

Last post Vapor

637

NEU

M&A

01/05/25

101

53K

01/05/25

Last post jimbovb

101

53K

NEU

Ann: Update - Notification of buy-back - NEU

30/04/25

553

30/04/25

Last post

ASX News

553

See All Discussions

Timeline

Neuren appoints Daryl DeKarske to executive team
02 May 09:09	Share

Update - Notification of buy-back - NEU
02 May 08:09	Share

Update - Notification of buy-back - NEU
01 May 08:53	Share

Update - Notification of buy-back - NEU
30 Apr 07:55	Share

Update - Notification of buy-back - NEU
29 Apr 07:33	Share

Update - Notification of buy-back - NEU
28 Apr 09:08	Share

Virtual AGM online guide
24 Apr 09:26	Share

Notice of Annual General Meeting/Proxy Form
24 Apr 09:20	Share

Update - Notification of buy-back - NEU
24 Apr 08:53	Share

Update - Notification of buy-back - NEU
23 Apr 07:59	Share

Update - Notification of buy-back - NEU
22 Apr 08:42	Share

Update - Notification of buy-back - NEU
17 Apr 08:36	Share

Change of Director's Interest Notice - J Basile
16 Apr 16:52	Share

NEU confirms primary endpoints for Phase 3 trial in PMS
14 Apr 08:58	Share

Update - Notification of buy-back - NEU
07 Apr 08:26	Share

Update - Notification of buy-back - NEU
04 Apr 09:03	Share

Notification of cessation of securities - NEU
03 Apr 08:21	Share

Update - Notification of buy-back - NEU
03 Apr 07:56	Share

Appendix 4G
03 Apr 07:53	Share

2024 Annual Report to shareholders
03 Apr 07:51	Share

Update - Notification of buy-back - NEU
02 Apr 08:31	Share

Update - Notification of buy-back - NEU
01 Apr 08:49	Share

Update - Notification of buy-back - NEU
31 Mar 09:06	Share

Update - Notification of buy-back - NEU
28 Mar 08:55	Share

Neuren initiates development of NNZ-2591 to treat HIE
27 Mar 09:36	Share

Update - Notification of buy-back - NEU
27 Mar 08:55	Share

Update - Notification of buy-back - NEU
26 Mar 08:30	Share

Update - Notification of buy-back - NEU
25 Mar 08:18	Share

Update - Notification of buy-back - NEU
24 Mar 08:47	Share

Update - Notification of buy-back - NEU
21 Mar 07:30	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.66		Change 0.860(7.29%)		Mkt cap ! $1.576B

Open	High	Low	Value	Volume
$11.74	$12.79	$11.67	$5.161M	415.8K

Buyers (Bids)

No.	Vol.	Price($)
18	1256	$12.64

Sellers (Offers)

Price($)	Vol.	No.
$12.66	885	3

View Market Depth

No.	Vol.	Price($)
4	54	12.500
9	939	12.490
12	1850	12.480
6	2498	12.470
6	2274	12.460

Price($)	Vol.	No.
12.510	636	16
12.520	2199	10
12.530	2375	12
12.540	2892	13
12.550	1686	11

Last trade - 14.38pm 02/05/2025 (20 minute delay)


Last $12.57		Change 0.860 ( 6.19 %)
Open	High	Low	Volume
$11.70	$12.78	$11.69	94351
Last updated 14.57pm 02/05/2025 ?

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Listen: HotCopper Podcast 011 - Pre-election special - Showdown time Dutton vs Albanese

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome.

Neuren set for FDA talks on trial to treat developmental genetic disorders

Neuren Pharmaceuticals is set to enter talks with the Us Food and Drug Administration about its upcoming trial.

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News